A groundbreaking clinical trial has demonstrated that a single injection of the gene editing therapy VERVE-102 can reduce LDL cholesterol by up to 84% in patients with severe hypercholesterolemia. The phase 1 study, published in The New England Journal of Medicine, represents the first successful human trial of in vivo base editing to treat cardiovascular disease.
VERVE-102 Cholesterol Reduction by Dose
Percentage reduction in LDL cholesterol at 180 days, by treatment group
Source: NEJM, 2024 | Georgian Medical Journal News
Revolutionary Base Editing Technology Shows Promise
VERVE-102 uses CRISPR-Cas base editing to permanently modify the PCSK9 gene in liver cells, effectively turning off production of a protein that normally prevents cholesterol removal from the blood. The therapy consists of lipid nanoparticles containing guide RNA and base editor components delivered through a single intravenous infusion.
Dr. Sekar Kathiresan, chief executive of Verve Therapeutics and co-corresponding author of the study, noted that this approach could potentially provide lifelong cholesterol reduction with a one-time treatment. The clinical implications extend far beyond current statin therapy, which requires daily medication adherence.
Safety Profile and Participant Response
The study enrolled 10 participants with heterozygous familial hypercholesterolemia and established atherosclerotic cardiovascular disease. All participants had baseline LDL cholesterol levels exceeding 70 mg/dL despite maximum tolerated lipid-lowering therapy, according to the New England Journal of Medicine publication.
No serious adverse events were attributed to VERVE-102 during the 180-day follow-up period. Mild infusion-related symptoms occurred in some participants but resolved within 24-48 hours. Laboratory monitoring showed no significant changes in liver function tests or other safety markers, suggesting the therapy was well-tolerated at all dose levels.
Implications for Cardiovascular Disease Prevention
The dramatic cholesterol reductions achieved with VERVE-102 could transform prevention strategies for cardiovascular disease, particularly in patients with genetic forms of hypercholesterolemia who struggle to achieve target levels with conventional therapy. The World Health Organization estimates that cardiovascular diseases cause 17.9 million deaths annually worldwide.
Current guidelines recommend LDL cholesterol targets below 55 mg/dL for patients at very high cardiovascular risk. In this trial, participants receiving the highest dose of VERVE-102 achieved mean LDL levels of 33 mg/dL at 180 days, well below recommended targets. This level of reduction typically requires combination therapy with multiple medications and is difficult to maintain long-term due to adherence challenges.
Next Steps and Regulatory Pathway
Based on these promising results, Verve Therapeutics plans to initiate phase 2 studies in 2025 with larger patient populations and longer follow-up periods. The company is also developing VERVE-101, a similar therapy for patients with homozygous familial hypercholesterolemia, a more severe genetic condition.
The FDA’s guidance for gene and cell therapy products will likely require extensive safety data before approval, given the permanent nature of the genetic modification. Long-term follow-up studies tracking participants for potential off-target effects will be crucial for regulatory review.
VERVE-102 achieved dose-dependent reductions in LDL cholesterol ranging from 39% to 84% at 180 days, with the highest dose producing sustained effects below target levels recommended for high-risk patients.
— Dr. Sekar Kathiresan, Verve Therapeutics (New England Journal of Medicine, 2024)
Key takeaways
- Single injection of VERVE-102 reduced LDL cholesterol by up to 84% in patients with severe hypercholesterolemia
- Base editing technology permanently modifies PCSK9 gene to enhance cholesterol removal from blood
- No serious adverse events were observed during 180-day follow-up period in phase 1 trial
- Results could transform cardiovascular disease prevention for patients unable to achieve targets with conventional therapy
Frequently asked questions
How does VERVE-102 differ from existing cholesterol medications?
Unlike statins or PCSK9 inhibitors that require ongoing treatment, VERVE-102 permanently modifies the PCSK9 gene with a single injection. This base editing approach could provide lifelong cholesterol reduction without daily medication adherence requirements.
Who would be eligible for VERVE-102 treatment?
The current trial focused on patients with familial hypercholesterolemia and established cardiovascular disease who cannot achieve target cholesterol levels despite maximum conventional therapy. Future studies may expand eligibility criteria based on safety and efficacy data.
What are the potential long-term risks of genetic modification?
While no serious adverse events occurred in the 180-day study period, long-term safety data are still being collected. Regulatory approval will likely require extensive follow-up to monitor for any off-target genetic effects or unintended consequences of permanently reducing PCSK9 function.
The successful demonstration of in vivo base editing for cardiovascular disease represents a paradigm shift toward precision genetic therapies that could address root causes rather than managing symptoms. As longer-term safety data emerge and manufacturing processes scale, VERVE-102 may offer hope for millions of patients worldwide who struggle to control cholesterol levels despite existing treatments, potentially preventing countless heart attacks and strokes through a single therapeutic intervention.
Source: In Vivo Base Editing of PCSK9 with VERVE-102 for Hypercholesterolemia
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Medically reviewed by Prof. Giorgi Pkhakadze, MD, MPH, PhD. Spotted an error? Contact the editorial team.
